Harvest Declares Big Pharma Split Corp. September 2025 Distributions

Harvest Portfolios Group Inc. has announced significant distributions for Big Pharma Split Corp. for the month and quarter ending September 30, 2025. For Class A shareholders (PRM:TSX), a monthly cash distribution of $0.1031 per share has been declared, set to be payable on October 9, 2025. Shareholders must be on record by the close of business on September 29, 2025, to qualify for this distribution.

Additionally, a quarterly cash distribution of $0.1250 per Preferred share (PRM.PR.A:TSX) has also been established for the same period. This payment will likewise be made on October 9, 2025, with the same record date of September 29, 2025, for Preferred shareholders.

Founded in 2009, Harvest is a well-established independent Canadian Investment Fund Manager, currently overseeing assets amounting to $8.8 billion on behalf of Canadian investors. With a focus on long-term wealth preservation and growth, Harvest emphasizes the importance of investing in high-quality businesses. This investment philosophy underpins various exchange-traded funds (ETFs) offered by the company, which primarily employ covered call strategies across multiple asset classes.

For further details regarding these distributions or to learn more about Harvest's investment strategies, stakeholders can visit the Harvest Portfolios website or contact their support via email or phone. Media inquiries can be directed to Caroline Grimont, Senior Vice President of Marketing, via her provided email.

Investors should always be aware of potential brokerage fees associated with buying or selling shares in the investment fund and should review relevant disclosure documents for comprehensive information regarding the funds. Overall, this announcement will be of interest to current and potential investors looking for reliable income from their investment in Big Pharma Split Corp.

**Market Analysis and Advice on Big Pharma Split Corp. Distributions**

Harvest Portfolios Group Inc. has recently announced its September 2025 distributions for Big Pharma Split Corp., declaring a monthly cash distribution of $0.1031 per Class A share (PRM:TSX) and a quarterly distribution of $0.1250 per Preferred share (PRM.PR.A:TSX). These distributions, payable on October 9, 2025, are set to attract both income-focused investors and those looking for exposure in the pharmaceutical sector.

For investors considering Class A shares, the monthly distribution of $0.1031 provides an annualized yield that can be appealing in the current low-interest-rate environment. With ongoing inflation concerns, many investors are seeking stocks that can provide consistent income and potential for capital appreciation. The robust monthly distribution suggests that Harvest expects stable cash flows from its underlying investments in pharmaceutical stocks, which have historically performed well even during economic downturns.

Preferred shares offer another avenue for income, with a quarterly distribution of $0.1250. Preferred shares tend to be less volatile and can provide fixed income, making them a solid option for risk-averse investors. Concentrated exposure to the pharmaceutical sector, particularly in a healthcare-focused investment vehicle, can be a prudent hedge against macroeconomic uncertainties.

Looking ahead, investors should carefully assess both the risks and opportunities associated with Big Pharma Split Corp. The pharmaceutical sector faces uncertainties such as regulatory changes, patent expirations, and evolving market dynamics. However, the increasing demand for healthcare solutions and innovation in drug development positions the sector for growth.

In conclusion, Big Pharma Split Corp. may be an attractive investment for those looking to enhance their portfolios with income-generating assets. Investors should conduct their due diligence, considering their risk tolerance and investment goals, before making any decisions. As always, diversifying holdings remains a sound strategy in navigating the complexities of the market.